News | January 13, 2022
Normalised quarter with impending margin pressure: ICICI Direct
ICICI Direct gives a preview on the earnings narrative for Q3FY22
ICICI Direct gives a preview on the earnings narrative for Q3FY22
It is the generic version of molnupiravir
The brand is now available pan-India through their distribution partner
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
A toll-free helpline to be set up to help doctors and patients
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
Natco Pharma has received approval for Covid 19 drug molnupiravir capsules 200 mg. for Indian market, which will be sold under brand name Molnunat
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
The product is expected to be available in a week’s time
Subscribe To Our Newsletter & Stay Updated
